Clinical Effects of Pramipexole Dihydrochloride Sustained-Release Tablets Combined with Hemodialysis Filtration in the Treatment of Uremia Complicated with Restless Leg Syndrome
Objective To investigate the effects of pramipexole dihydrochloride sustained-release tablets combined with hemodialysis filtration(HDF)on uremia(URE)complicated with restless leg syndrome(RLS).Methods Selected 74 patients with URE complicated with RLS admitted to Fengcheng People's Hospital from May 2022 to January 2024.Divided into observation group and control group according to the method of random number table,37 cases in each group.The control group underwent HDF,while the observation group was treated with combination therapy of pramipexole dihydrochloride sustained-release tablets.The International Rating Scale for Restless Leg Syndrome(IRLS)scores,biochemical indicators,sleep quality,anxiety level and adverse reactions between the two groups were compared.Results After treatment,the observation group had significantly lower scores on the IRLS,Hamilton Anxiety Scale(HAMA),and Pittsburgh Sleep Quality Index(PSQI)compared to the control group,and the levels of urea nitrogen(BUN),β2-microglobulin(β2-MG),and parathyroid hormone(PTH)in two groups were lower comparing with those before treatment(P＜0.05).But there was no statistically significant difference in the comparison between the groups(P＞0.05).The adverse reactions of two groups were compared,which showed no statistical difference(P＞0.05).Conclusion The combination of pramipexole dihydrochloride sustained-release tablets and HDF in the treatment of patients with URE complicated with RLS can alleviate the condition of RLS,effectively improve biochemical indicators,relieve anxiety symptoms and enhance sleep quality,which is safe and effective.
UremiaRestless leg syndromePramipexole dihydrochloride sustained-release tabletsHemodialysis filtration
NETL
NSTL
万方数据
